You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行報告》花旗下調輝瑞(PFE.US)目標價至35美元 評級「中性」
花旗發表報告指,輝瑞(PFE.US)進行重組及下調新冠藥物指引,屬關注重點,維持其「中性」評級,目標價由42美元下調至35美元。該評級是基於市場預期扣除新冠藥物後,收入有短期溫和增長;在產品管線上,短期催化劑不多;而除諾和諾德(NVO.US)及禮來(LLY.US)外,行業估值偏低。該行期望輝瑞重組及完成收購癌症藥廠Seagen後,集中提升主要產品管線。 在美股同業中,花旗偏好禮來、默克(MRK.US)、艾伯維(ABBV.US),歐洲同業中偏好阿斯利康、諾和諾德、羅氏、賽諾菲。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account